Attached files

file filename
EX-23.1 - CONSENT OF KOST FORER GABBAY & KASIERER, A MEMBER OF ERNST & YOUNG GLOBAL - PLURISTEM THERAPEUTICS INCf10k2021ex23-1_pluristem.htm
EX-32.2 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2021ex32-2_pluristem.htm
EX-32.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2021ex32-1_pluristem.htm
EX-31.1 - CERTIFICATION - PLURISTEM THERAPEUTICS INCf10k2021ex31-1_pluristem.htm
EX-23.2 - CONSENT OF KESSELMAN & KESSELMAN, INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM - PLURISTEM THERAPEUTICS INCf10k2021ex23-2_pluristem.htm
EX-10.30 - LETTER AGREEMENT BY AND BETWEEN PLURISTEM LTD. AND CHEN FRANCO-YEHUDA, DATED SEP - PLURISTEM THERAPEUTICS INCf10k2021ex10-30_pluristem.htm
EX-10.29 - LETTER AGREEMENT BY AND BETWEEN PLURISTEM LTD. AND YAKY YANAY, DATED SEPTEMBER 1 - PLURISTEM THERAPEUTICS INCf10k2021ex10-29_pluristem.htm
EX-10.28 - LETTER AGREEMENT BY AND BETWEEN PLURISTEM LTD. AND ROSE HIGH TECH LTD., DATED SE - PLURISTEM THERAPEUTICS INCf10k2021ex10-28_pluristem.htm
EX-10.20 - FORM OF RESTRICTED STOCK UNIT AGREEMENT (EMPLOYEES) UNDER THE 2019 EQUITY COMPEN - PLURISTEM THERAPEUTICS INCf10k2021ex10-20_pluristem.htm
EX-10.19 - FORM OF RESTRICTED SHARE UNIT AGREEMENT (ISRAELI DIRECTORS AND OFFICERS) UNDER T - PLURISTEM THERAPEUTICS INCf10k2021ex10-19_pluristem.htm
EX-10.18 - FORM OF RESTRICTED SHARE UNIT AGREEMENT UNDER THE 2019 EQUITY COMPENSATION PLAN - PLURISTEM THERAPEUTICS INCf10k2021ex10-18_pluristem.htm
10-K - ANNUAL REPORT - PLURISTEM THERAPEUTICS INCf10k2021_pluristemtherap.htm

Exhibit 31.2

 

CERTIFICATION

 

I, Chen Franco-Yehuda, certify that:

 

1.I have reviewed this annual report on Form 10-K for the year ended June 30, 2021, of Pluristem Therapeutics Inc.;

 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

 

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

 

4.The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) and have:

 

a.Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

 

b.Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

 

c.Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

 

d.Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect,the registrant’s internal control over financial reporting; and

 

5.The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

 

a.All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

 

b.Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

 

Dated: September 13, 2021

 

By: /s/ Chen Franco-Yehuda  
  Chen Franco-Yehuda  
  Chief Financial Officer  
  (Principal Financial Officer)